Literature DB >> 12942158

Molecular actions of calcineurin inhibitors.

Majed M Hamawy1.   

Abstract

The immunosuppressive drugs cyclosporin A and FK-506, also called calcineurin inhibitors, have been useful for treating immune system-mediated diseases and have truly revolutionized allograft transplantation. Both drugs block T-cell proliferation by mechanisms that involve the inhibition of the key signaling phosphatase calcineurin, hence, the name calcineurin inhibitors. The inhibition of calcineurin activation by cyclosporin A and FK-506 blocks T-cell receptor-mediated production of interleukin-2 (IL-2), a growth factor critical for T-cell proliferation. Recent studies, however, suggest that the effects of the drugs are not limited to blocking calcineurin activation and IL-2 production. This review discusses the molecular actions of cyclosporin A and FK-506. (c) 2003 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942158     DOI: 10.1358/dnp.2003.16.5.829315

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  20 in total

1.  Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.

Authors:  Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

2.  A novel library screen identifies immunosuppressors that promote osteoblast differentiation.

Authors:  Ariana Darcy; Micah Meltzer; Joseph Miller; Steven Lee; Scott Chappell; Kris Ver Donck; Monty Montano
Journal:  Bone       Date:  2012-03-13       Impact factor: 4.398

3.  Myeloid-Derived Suppressor Cells Ameliorate Cyclosporine A-Induced Hypertension in Mice.

Authors:  Valorie L Chiasson; Kelsey R Bounds; Piyali Chatterjee; Lochana Manandhar; Abhinandan R Pakanati; Marcos Hernandez; Bilal Aziz; Brett M Mitchell
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 4.  Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments.

Authors:  Joseph G Kamel; Paul S Yamauchi
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 3.923

5.  Hypoxia enhances high-voltage-activated calcium currents in rat primary cortical neurons via calcineurin.

Authors:  Kun Xiang; Damien Earl; Trisha Dwyer; Brian L Behrle; Elizabeth I Tietz; L John Greenfield
Journal:  Epilepsy Res       Date:  2012-01-13       Impact factor: 3.045

6.  Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.

Authors:  Xiaofei He; Aixia Dou; Saran Feng; Ashley Roman-Rivera; Caleb Hawkins; Lauren Lawley; Jiajia Zhang; Mark Wunderlich; Benjamin Mizukawa; Stephanie Halene; Amisha Patel; Jing Fang
Journal:  Exp Hematol       Date:  2020-05-08       Impact factor: 3.084

7.  Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421.

Authors:  Raúl Pardo; Emilie Colin; Etienne Régulier; Patrick Aebischer; Nicole Déglon; Sandrine Humbert; Frédéric Saudou
Journal:  J Neurosci       Date:  2006-02-01       Impact factor: 6.167

8.  TNF-α contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT.

Authors:  Susana Alvarez; Almudena Blanco; Manuel Fresno; Ma Ángeles Muñoz-Fernández
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

9.  Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors:  Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

10.  DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?

Authors:  Petra C E van Kesteren; Rudolf B Beems; Mirjam Luijten; Joke Robinson; Annemieke de Vries; Harry van Steeg
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.